Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia pharmacokinetics during pregnancy in women with chronic inflammatory diseases
NL-OMON51965Phase 1Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis and 4 more, sponsored by UCB. Primary endpoint: Predose and postdose plasma certolizumab pegol concentrations during pregnancy relative to postpartum. Started Nov 2021; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)plaque psoriasisCrohn's diseaseaxial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON51965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51965.